Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Lysergamides

AL-LAD

C22H27N3O CAS 65527-61-9 Analytical reference material — not for human consumption
AL-LAD, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
AL-LAD
IUPAC name
(6aR,9R)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Parent CAS number (reference)
65527-61-9
Molecular formula
C22H27N3O
Molecular weight
349.5 g/mol
InChIKey
JCQLEPDZFXGHHQ-OXQOHEQNSA-N
PubChem
CID 15227511
Source
PubChem
Verified synonyms & catalog abbreviations
6-allyl-6-nor-LSD N-Allylnor-LSD ALLAD AL LAD

Verified Neurochemical & Toxicological Intelligence

AL-LAD

N6-Allyl Lysergamide (5-HT2A Partial Agonist) Lysergamide
Verified PubChem & CAS Identity C22H27N3O · CAS 65527-61-9 · CID 15227511
Calibrated Physical Form Dissolved Liquid Solution (µg Calibrated)
≥98% Analytical Purity Verified 349.5 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

5-HT₂ₐ Perceptual & Visual Signaling Partial Agonist
5-HT₁ₐ / 5-HT₂c Serotonergic Modulation Active
D₂ / Adrenergic Dopaminergic / Somatic Tone Moderate

Direct active N6-allyl-nor-LSD analogue (not a prodrug to LSD-25) with potent 5-HT2A/5-HT1A receptor agonism and modified N6 steric binding.

Biotransformation & Active Metabolites

Directly active at 5-HT2A without hydrolyzing to LSD-25.

Temporal Pharmacokinetics

N6-Allyl Lysergamide (5-HT2A Partial Agonist) — Supplied as dissolved liquid solution; differs from 1P-LSD/1cP-LSD by being shorter (6–9 h vs 8–12 h) with brighter visual geometry and lighter cognitive introspection at low-to-common amounts, though steep above 200 ug.

  1. Onset 30–75 min
  2. Peak Window 1.5–3.5 h
  3. Total Window 6–9 h
  4. Residual / Half-Life 3–5 h after-effects

Supplied as dissolved liquid solution; differs from 1P-LSD/1cP-LSD by being shorter (6–9 h vs 8–12 h) with brighter visual geometry and lighter cognitive introspection at low-to-common amounts, though steep above 200 ug.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
20–40 ug
Cognitive & Sensory

Subtle threshold receptor activity (N6-Allyl Lysergamide (5-HT2A Partial Agonist)).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
40–80 ug
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
80–160 ug
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
160–250 ug
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
250+ ug
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Lithium salts

Strongly documented to provoke acute tonic-clonic seizures, fugue states, and severe psychotic episodes with lysergamides.

Tramadol

Lowers seizure threshold alongside 5-HT2A excitation.

Elevated Hazard — Avoid

Cannabis & Strong Stimulants (Cathinones, Amphetamines, Cocaine)

Exponentially amplifies thought loops, tachycardia, anxiety, and acute paranoia.

Caution / Receptor Attenuation

SSRIs / SNRIs & Benzodiazepines

Chronic SSRIs and acute benzodiazepines markedly attenuate 5-HT2A perceptual effects.

Structural Isomer & Sibling Comparison

Supplied as dissolved liquid solution; differs from 1P-LSD/1cP-LSD by being shorter (6–9 h vs 8–12 h) with brighter visual geometry and lighter cognitive introspection at low-to-common amounts, though steep above 200 ug.

Physicochemical Stability & Storage

Physical Form: Clear, colorless calibrated liquid solution for microgram (µg) volumetric measurement. · Supplied pre-dissolved in analytical carrier; sensitive to chlorine/tap water.

Highly sensitive to UV light, heat, and chlorine; store airtight in amber glass under cold/refrigerated conditions.

Cross-Tolerance & Dependence Profile

Immediate rapid 5-HT2A receptor downregulation within hours, cross-tolerant with all tryptamines and phenethylamines; baseline sensitivity typically resets over 10–14 days. Non-addictive physiologically.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
5-HT₂ₐ Serotonin receptor 5-HT2A

5-HT is the laboratory name for serotonin. 2A is one subtype of its receptor. Lysergamide, tryptamine, and many 2C-family cards cite this receptor.

Kᵢ Binding tightness in nanomoles

Ki says how tightly a compound sits on a receptor in a binding test. It is written in nanomoles per litre. A Ki of 1 nM means very tight binding in that experiment.

curve Concentration-response curve

The response curve plots concentration along the bottom and the measured laboratory response up the side. It is usually flat, then steep, then flat again near the top. EC50 sits on the steep middle.

T½ Half-life

Half-life is the time it takes a measured concentration to fall by half. After one half-life, half remains. After another, a quarter of the original measurement remains.

CAS CAS registry number

A CAS number is a passport number for one chemical entry in the CAS registry. The free base and a salt of the same parent usually have different CAS numbers.

1 mg / µg Calibrated Physical Form (1 mg Tablets, µg Liquid, Crystal)

Milligram-scale benzodiazepines are supplied as 1 mg tablets (1 tablet = 1 mg), microgram lysergamides as dissolved liquid (µg), and standard compounds as pure crystal or powder.

MAOI / IMAO Monoamine Oxidase Inhibitors (MAOIs)

Compounds and medications that block the enzyme responsible for breaking down serotonin, dopamine, and norepinephrine; combining them with monoamine releasers is life-threatening.

5-HT ↑↑ Serotonergic Overload (Serotonin Toxicity)

A potentially fatal medical emergency caused by excessive synaptic serotonin (for example when mixing two serotonin releasers, MAOIs, or tramadol), marked by hyperthermia and neuromuscular rigidity.

Comprehensive Analytical & Toxicological Monograph

AL-LAD ((6aR,9R)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; CAS 65527-61-9, PubChem CID 15227511) is a lysergamide reference compound (C22H27N3O, 349.5 g/mol) classified pharmacologically as a N6-Allyl Lysergamide (5-HT2A Partial Agonist). Direct active N6-allyl-nor-LSD analogue (not a prodrug to LSD-25) with potent 5-HT2A/5-HT1A receptor agonism and modified N6 steric binding. Directly active at 5-HT2A without hydrolyzing to LSD-25. In published observational and toxicological literature, threshold response is noted at 20–40 ug, light range at 40–80 ug, common reference range at 80–160 ug, strong intensity at 160–250 ug, and heavy/adverse territory at 250+ ug, with an onset of 30–75 min, peak window of 1.5–3.5 h, and total duration of 6–9 h (3–5 h after-effects). Supplied as dissolved liquid solution; differs from 1P-LSD/1cP-LSD by being shorter (6–9 h vs 8–12 h) with brighter visual geometry and lighter cognitive introspection at low-to-common amounts, though steep above 200 ug. Critical contraindications include Lithium salts, Tramadol.

Chemical Architecture & Structural Profile

AL-LAD ((6aR,9R)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide) is a reference compound belonging to the Lysergamides class, characterized by the molecular formula C22H27N3O and a molar mass of 349.5 g/mol. The parent molecule is indexed under CAS registry number 65527-61-9 and in the NCBI PubChem database as CID 15227511 (Standard InChIKey: JCQLEPDZFXGHHQ-OXQOHEQNSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), AL-LAD is indexed within the Lysergamides structural group. Toxicological notes (PsychonautWiki): toxic dose is unknown, extremely low toxicity. Dependence liability (PsychonautWiki): not habit-forming. Documented cross-tolerance class: psychedelic. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)